Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab vs Docetaxel in Advanced NSCLC (RATIONALE-303)
NCT03358875Phase 3Completed
- Sponsor
- BeiGene
- Start
- Nov 2017
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Nov 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03358875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358875.